Chailurkit L O, Rajatanavin R, Teerarungsikul K
Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
J Med Assoc Thai. 1996 Oct;79(10):661-6.
Five commercial kits for estimating FT4 in serum of 59 euthyroid control and 38 patients with severe NTI were studied: one non analog method (Gammacoat two step RIA, Clinical Assay) and four different analog methods (Amerlex-M RIA, Amersham; Enzymun test competitive enzyme immunoassay, Boehringer Mannheim; Amerlite chemiluminescence immunoassay, Kodak Clinical Diagnostics; Berilux chemiluminescence immunoassay, Behring) compared with equilibrium dialysis (Eq) method. Serum FT4 estimates in NTI patients measured by all commercial kits in this study yielded results comparable with those by equilibrium dialysis. The proportions of serum FT4 values concordant with FT4 (Eq) in each kit were 76.3, 76.3, 76.3, 68.4 and 78.9 per cent respectively. The percentage of NTI patients who had serum FT4 values lower than the reference levels of the methods used were 21.2, 26.3, 7.9, 15.8, 18.4 and 18.4 per cent respectively. No patient with low serum FT4 (Eq) level had subnormal or high serum TSH value. However, 4 out of 6 patients with high serum FT4 (Eq) values had depressed serum TSH values. All of them also had elevation of serum FT4 estimates measured by all kits. Serum FT4 estimates measured by all methods correlated well with FT4 (Eq) levels within the NTI group.
研究了用于估算59例甲状腺功能正常对照者和38例重度非甲状腺疾病（NTI）患者血清游离甲状腺素（FT4）的五种商用试剂盒：一种非类似物方法（Gammacoat两步放射免疫分析，Clinical Assay）和四种不同的类似物方法（Amerlex - M放射免疫分析，Amersham；Enzymun test竞争酶免疫分析，Boehringer Mannheim；Amerlite化学发光免疫分析，Kodak Clinical Diagnostics；Berilux化学发光免疫分析，Behring），并与平衡透析（Eq）法进行比较。本研究中所有商用试剂盒测量的NTI患者血清FT4估算值与平衡透析法的结果相当。各试剂盒中血清FT4值与FT4（Eq）一致的比例分别为76.3%、76.3%、76.3%、68.4%和78.9%。血清FT4值低于所用方法参考水平的NTI患者百分比分别为21.2%、26.3%、7.9%、15.8%、18.4%和18.4%。血清FT4（Eq）水平低的患者血清促甲状腺激素（TSH）值均未低于正常或高于正常。然而，血清FT4（Eq）值高的6例患者中有4例血清TSH值降低。他们所有人血清FT4估算值也都升高。所有方法测量的血清FT4估算值与NTI组内的FT4（Eq）水平相关性良好。
